Sym015 shows superior specificity compared to TKIs for NSCLC
Sym015 shows superior specificity compared to TKIs for NSCLC
Brigatinib for NSCLC, latest research and overcoming complications
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer
Do immune checkpoint inhibitors work in EGFR mutant lung cancer?
Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutation-positive advanced melanoma
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma
New oncogenic drivers in NSCLC
The potential of KRAS inhibitors for non-small-cell lung cancer
Novel treatment strategies for prostate cancer: Senescence, senolytics and myeloid derived suppressor cells
Immune checkpoint based approaches in AML and MDS